Advanced Cell Technology, Inc. (“ACT”);(OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs).

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data on September 26, 2011, from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the start of patient dosing in an international Phase 1/2 clinical trial of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) -- two clinically validated targets in non-small cell lung cancer (NSCLC).

Flexible Stenting Solutions Inc. announced today the successful treatment of the first two patients enrolled in the OPEN (Evaluation of Safety and Efficacy of the FlexStent^® FemorOPopliteal Self-Expanding StENt System) clinical trial.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the second pivotal Phase 3 clinical trial (Study 103) of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada^(R) (emtricitabine/tenofovir disoproxil fumarate) based on the proportion of subjects who achieved HIV RNA levels (viral load) of less than 50 copies/mL.

In the second trial following the largest notification by the Clark County Health Department that 50,000 residents of Nevada may be infected with hepatitis, plaintiff James Arnold took the stand today and described the first day he noticed his wife was sick following her colonoscopy treatment at the Endoscopy Center of Southern Nevada.